Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant-Reference-Cited by-同舟云学术

Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant

Published:2024-04 Issue:7 Volume:65 Page:1016-1019
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cao Yaqing¹²³,Shang Jingjing¹²³,Zhai Yingying¹²³,Wang Qingyuan¹²³,Yan Lingzhi¹²³,Shi Xiaolan¹²³,Wang Jing¹²³,Yao Ying¹²³,Zhou Huifen¹²³,Sun Aining¹²³,Miao Miao¹²³,Fu Chengcheng¹²³,Jin Song¹²³^ORCID

Affiliation:

1. National Clinical Research Centre for Haematologic Diseases, Jiangsu Institute of Haematology, The First Affiliated Hospital of Soochow University, Suzhou, China

2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Centre of Haematology, Soochow University, Suzhou, China

3. Key Laboratory of Thrombosis and Haemostasis of Ministry of Health, Suzhou, China

Funder

National Natural Science Foundation of China

Grants from the Jiangsu Province of China

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2329322

Reference16 articles.

1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

2. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria

3. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

4. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders

5. Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy